Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02399371
Title Pembrolizumab in Treating Patients With Malignant Mesothelioma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Chicago
Indications

malignant pleural mesothelioma

peritoneal mesothelioma

Therapies

Pembrolizumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.